APO Research
Talk to an analyst

APO RESEARCH · REPORT

Manmade Version of Somatostatin

Compare research editions
View pricing & licenses

Selected research

Industry Research

Manmade Version of Somatostatin Industry Research Report 2026

28 December 2025130 pages

Choose your research edition.

Industry ResearchManmade Version of Somatostatin Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Manmade Version of Somatostatin Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Manmade Version of Somatostatin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Manmade Version of Somatostatin Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Manmade Version of Somatostatin Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Manmade Version of Somatostatin market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Manmade Version of Somatostatin is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Manmade Version of Somatostatin is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Manmade Version of Somatostatin is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Manmade Version of Somatostatin include Advanz Pharma, Chiesi Farmaceutici S.p.A, Cipla, Fresenius Kabi, Gland Pharma, Heritage Pharmaceuticals, Ipsen, Mylan and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Manmade Version of Somatostatin market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Manmade Version of Somatostatin Market by Company

Advanz Pharma

Chiesi Farmaceutici S.p.A

Cipla

Fresenius Kabi

Gland Pharma

Heritage Pharmaceuticals

Ipsen

Mylan

Novartis

Recordati Rare Diseases

Sagent Pharmaceuticals

Sun Pharmaceutical

Teva

West-Ward Pharmaceuticals

Chengdu Tiantaishan pharmaceutical

Hainan Shuangcheng Pharmaceuticals

Hybio Pharmaceutical

Sihuan Pharmaceutical

Suzhou Tianma Pharmaceutical

Manmade Version of Somatostatin Segment by Type

Pasireotide

Lanreotide

Octreotide

Other

Manmade Version of Somatostatin Segment by Application

Cushing Syndrome

Neuroendocrine Tumors

Acromegaly

Other

Manmade Version of Somatostatin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Manmade Version of Somatostatin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Manmade Version of Somatostatin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Manmade Version of Somatostatin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Manmade Version of Somatostatin manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Manmade Version of Somatostatin by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Manmade Version of Somatostatin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Manmade Version of Somatostatin Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Manmade Version of Somatostatin Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Manmade Version of Somatostatin Sales Market Share by Manufacturers (2021-2026) Table 8. Global Manmade Version of Somatostatin Revenue of Manufacturers (2021-2026) Table 9. Global Manmade Version of Somatostatin Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Manmade Version of Somatostatin Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Manmade Version of Somatostatin Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Manmade Version of Somatostatin, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Manmade Version of Somatostatin, Product Type & Application Table 14. Global Manmade Version of Somatostatin Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Manmade Version of Somatostatin by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Advanz Pharma Company Information Table 19. Advanz Pharma Business Overview Table 20. Advanz Pharma Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Advanz Pharma Manmade Version of Somatostatin Product Portfolio Table 22. Advanz Pharma Recent Developments Table 23. Chiesi Farmaceutici S.p.A Company Information Table 24. Chiesi Farmaceutici S.p.A Business Overview Table 25. Chiesi Farmaceutici S.p.A Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Chiesi Farmaceutici S.p.A Manmade Version of Somatostatin Product Portfolio Table 27. Chiesi Farmaceutici S.p.A Recent Developments Table 28. Cipla Company Information Table 29. Cipla Business Overview Table 30. Cipla Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Cipla Manmade Version of Somatostatin Product Portfolio Table 32. Cipla Recent Developments Table 33. Fresenius Kabi Company Information Table 34. Fresenius Kabi Business Overview Table 35. Fresenius Kabi Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Fresenius Kabi Manmade Version of Somatostatin Product Portfolio Table 37. Fresenius Kabi Recent Developments Table 38. Gland Pharma Company Information Table 39. Gland Pharma Business Overview Table 40. Gland Pharma Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Gland Pharma Manmade Version of Somatostatin Product Portfolio Table 42. Gland Pharma Recent Developments Table 43. Heritage Pharmaceuticals Company Information Table 44. Heritage Pharmaceuticals Business Overview Table 45. Heritage Pharmaceuticals Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Heritage Pharmaceuticals Manmade Version of Somatostatin Product Portfolio Table 47. Heritage Pharmaceuticals Recent Developments Table 48. Ipsen Company Information Table 49. Ipsen Business Overview Table 50. Ipsen Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Ipsen Manmade Version of Somatostatin Product Portfolio Table 52. Ipsen Recent Developments Table 53. Mylan Company Information Table 54. Mylan Business Overview Table 55. Mylan Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Mylan Manmade Version of Somatostatin Product Portfolio Table 57. Mylan Recent Developments Table 58. Novartis Company Information Table 59. Novartis Business Overview Table 60. Novartis Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Novartis Manmade Version of Somatostatin Product Portfolio Table 62. Novartis Recent Developments Table 63. Recordati Rare Diseases Company Information Table 64. Recordati Rare Diseases Business Overview Table 65. Recordati Rare Diseases Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Recordati Rare Diseases Manmade Version of Somatostatin Product Portfolio Table 67. Recordati Rare Diseases Recent Developments Table 68. Sagent Pharmaceuticals Company Information Table 69. Sagent Pharmaceuticals Business Overview Table 70. Sagent Pharmaceuticals Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Sagent Pharmaceuticals Manmade Version of Somatostatin Product Portfolio Table 72. Sagent Pharmaceuticals Recent Developments Table 73. Sun Pharmaceutical Company Information Table 74. Sun Pharmaceutical Business Overview Table 75. Sun Pharmaceutical Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Sun Pharmaceutical Manmade Version of Somatostatin Product Portfolio Table 77. Sun Pharmaceutical Recent Developments Table 78. Teva Company Information Table 79. Teva Business Overview Table 80. Teva Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Teva Manmade Version of Somatostatin Product Portfolio Table 82. Teva Recent Developments Table 83. West-Ward Pharmaceuticals Company Information Table 84. West-Ward Pharmaceuticals Business Overview Table 85. West-Ward Pharmaceuticals Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. West-Ward Pharmaceuticals Manmade Version of Somatostatin Product Portfolio Table 87. West-Ward Pharmaceuticals Recent Developments Table 88. Chengdu Tiantaishan pharmaceutical Company Information Table 89. Chengdu Tiantaishan pharmaceutical Business Overview Table 90. Chengdu Tiantaishan pharmaceutical Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Chengdu Tiantaishan pharmaceutical Manmade Version of Somatostatin Product Portfolio Table 92. Chengdu Tiantaishan pharmaceutical Recent Developments Table 93. Hainan Shuangcheng Pharmaceuticals Company Information Table 94. Hainan Shuangcheng Pharmaceuticals Business Overview Table 95. Hainan Shuangcheng Pharmaceuticals Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Hainan Shuangcheng Pharmaceuticals Manmade Version of Somatostatin Product Portfolio Table 97. Hainan Shuangcheng Pharmaceuticals Recent Developments Table 98. Hybio Pharmaceutical Company Information Table 99. Hybio Pharmaceutical Business Overview Table 100. Hybio Pharmaceutical Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Hybio Pharmaceutical Manmade Version of Somatostatin Product Portfolio Table 102. Hybio Pharmaceutical Recent Developments Table 103. Sihuan Pharmaceutical Company Information Table 104. Sihuan Pharmaceutical Business Overview Table 105. Sihuan Pharmaceutical Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Sihuan Pharmaceutical Manmade Version of Somatostatin Product Portfolio Table 107. Sihuan Pharmaceutical Recent Developments Table 108. Suzhou Tianma Pharmaceutical Company Information Table 109. Suzhou Tianma Pharmaceutical Business Overview Table 110. Suzhou Tianma Pharmaceutical Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Suzhou Tianma Pharmaceutical Manmade Version of Somatostatin Product Portfolio Table 112. Suzhou Tianma Pharmaceutical Recent Developments Table 113. Global Manmade Version of Somatostatin Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 114. Global Manmade Version of Somatostatin Sales by Region (2021-2026) & (K Units) Table 115. Global Manmade Version of Somatostatin Sales Market Share by Region (2021-2026) Table 116. Global Manmade Version of Somatostatin Sales by Region (2027-2032) & (K Units) Table 117. Global Manmade Version of Somatostatin Sales Market Share by Region (2027-2032) Table 118. Global Manmade Version of Somatostatin Revenue by Region (2021-2026) & (US$ Million) Table 119. Global Manmade Version of Somatostatin Revenue Market Share by Region (2021-2026) Table 120. Global Manmade Version of Somatostatin Revenue by Region (2027-2032) & (US$ Million) Table 121. Global Manmade Version of Somatostatin Revenue Market Share by Region (2027-2032) Table 122. North America Manmade Version of Somatostatin Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. North America Manmade Version of Somatostatin Sales by Country (2021-2026) & (K Units) Table 124. North America Manmade Version of Somatostatin Sales by Country (2027-2032) & (K Units) Table 125. North America Manmade Version of Somatostatin Revenue by Country (2021-2026) & (US$ Million) Table 126. North America Manmade Version of Somatostatin Revenue by Country (2027-2032) & (US$ Million) Table 127. Europe Manmade Version of Somatostatin Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Europe Manmade Version of Somatostatin Sales by Country (2021-2026) & (K Units) Table 129. Europe Manmade Version of Somatostatin Sales by Country (2027-2032) & (K Units) Table 130. Europe Manmade Version of Somatostatin Revenue by Country (2021-2026) & (US$ Million) Table 131. Europe Manmade Version of Somatostatin Revenue by Country (2027-2032) & (US$ Million) Table 132. Asia Pacific Manmade Version of Somatostatin Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Asia Pacific Manmade Version of Somatostatin Sales by Country (2021-2026) & (K Units) Table 134. Asia Pacific Manmade Version of Somatostatin Sales by Country (2027-2032) & (K Units) Table 135. Asia Pacific Manmade Version of Somatostatin Revenue by Country (2021-2026) & (US$ Million) Table 136. Asia Pacific Manmade Version of Somatostatin Revenue by Country (2027-2032) & (US$ Million) Table 137. South America Manmade Version of Somatostatin Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. South America Manmade Version of Somatostatin Sales by Country (2021-2026) & (K Units) Table 139. South America Manmade Version of Somatostatin Sales by Country (2027-2032) & (K Units) Table 140. South America Manmade Version of Somatostatin Revenue by Country (2021-2026) & (US$ Million) Table 141. South America Manmade Version of Somatostatin Revenue by Country (2027-2032) & (US$ Million) Table 142. Middle East and Africa Manmade Version of Somatostatin Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. Middle East and Africa Manmade Version of Somatostatin Sales by Country (2021-2026) & (K Units) Table 144. Middle East and Africa Manmade Version of Somatostatin Sales by Country (2027-2032) & (K Units) Table 145. Middle East and Africa Manmade Version of Somatostatin Revenue by Country (2021-2026) & (US$ Million) Table 146. Middle East and Africa Manmade Version of Somatostatin Revenue by Country (2027-2032) & (US$ Million) Table 147. Global Manmade Version of Somatostatin Sales by Type (2021-2026) & (K Units) Table 148. Global Manmade Version of Somatostatin Sales by Type (2027-2032) & (K Units) Table 149. Global Manmade Version of Somatostatin Sales Market Share by Type (2021-2026) Table 150. Global Manmade Version of Somatostatin Sales Market Share by Type (2027-2032) Table 151. Global Manmade Version of Somatostatin Revenue by Type (2021-2026) & (US$ Million) Table 152. Global Manmade Version of Somatostatin Revenue by Type (2027-2032) & (US$ Million) Table 153. Global Manmade Version of Somatostatin Revenue Market Share by Type (2021-2026) Table 154. Global Manmade Version of Somatostatin Revenue Market Share by Type (2027-2032) Table 155. Global Manmade Version of Somatostatin Price by Type (2021-2026) & (US$/Unit) Table 156. Global Manmade Version of Somatostatin Price by Type (2027-2032) & (US$/Unit) Table 157. Global Manmade Version of Somatostatin Sales by Application (2021-2026) & (K Units) Table 158. Global Manmade Version of Somatostatin Sales by Application (2027-2032) & (K Units) Table 159. Global Manmade Version of Somatostatin Sales Market Share by Application (2021-2026) Table 160. Global Manmade Version of Somatostatin Sales Market Share by Application (2027-2032) Table 161. Global Manmade Version of Somatostatin Revenue by Application (2021-2026) & (US$ Million) Table 162. Global Manmade Version of Somatostatin Revenue by Application (2027-2032) & (US$ Million) Table 163. Global Manmade Version of Somatostatin Revenue Market Share by Application (2021-2026) Table 164. Global Manmade Version of Somatostatin Revenue Market Share by Application (2027-2032) Table 165. Global Manmade Version of Somatostatin Price by Application (2021-2026) & (US$/Unit) Table 166. Global Manmade Version of Somatostatin Price by Application (2027-2032) & (US$/Unit) Table 167. Key Raw Materials Table 168. Raw Materials Key Suppliers Table 169. Manmade Version of Somatostatin Distributors List Table 170. Manmade Version of Somatostatin Customers List Table 171. Manmade Version of Somatostatin Industry Trends Table 172. Manmade Version of Somatostatin Industry Drivers Table 173. Manmade Version of Somatostatin Industry Restraints Table 174. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Manmade Version of Somatostatin Product Image Figure 5. Global Manmade Version of Somatostatin Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Manmade Version of Somatostatin Market Size (2021-2032) & (US$ Million) Figure 7. Global Manmade Version of Somatostatin Sales (2021-2032) & (K Units) Figure 8. Global Manmade Version of Somatostatin Average Price (US$/Unit) & (2021-2032) Figure 9. Pasireotide Product Image Figure 10. Lanreotide Product Image Figure 11. Octreotide Product Image Figure 12. Other Product Image Figure 13. Cushing Syndrome Product Image Figure 14. Neuroendocrine Tumors Product Image Figure 15. Acromegaly Product Image Figure 16. Other Product Image Figure 17. Global Manmade Version of Somatostatin Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Manmade Version of Somatostatin, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Manmade Version of Somatostatin Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Manmade Version of Somatostatin Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Manmade Version of Somatostatin Sales by Region in 2025 Figure 23. Global Manmade Version of Somatostatin Revenue by Region in 2025 Figure 24. North America Manmade Version of Somatostatin Market Size by Country in 2025 Figure 25. North America Manmade Version of Somatostatin Sales Market Share by Country (2021-2032) Figure 26. North America Manmade Version of Somatostatin Revenue Market Share by Country (2021-2032) Figure 27. United States Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Mexico Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Manmade Version of Somatostatin Market Size by Country in 2025 Figure 31. Europe Manmade Version of Somatostatin Sales Market Share by Country (2021-2032) Figure 32. Europe Manmade Version of Somatostatin Revenue Market Share by Country (2021-2032) Figure 33. Germany Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Russia Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Spain Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Switzerland Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Sweden Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Poland Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Asia Pacific Manmade Version of Somatostatin Market Size by Country in 2025 Figure 44. Asia Pacific Manmade Version of Somatostatin Sales Market Share by Country (2021-2032) Figure 45. Asia Pacific Manmade Version of Somatostatin Revenue Market Share by Country (2021-2032) Figure 46. China Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Japan Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South Korea Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. India Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Australia Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Taiwan Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. South America Manmade Version of Somatostatin Market Size by Country in 2025 Figure 55. South America Manmade Version of Somatostatin Sales Market Share by Country (2021-2032) Figure 56. South America Manmade Version of Somatostatin Revenue Market Share by Country (2021-2032) Figure 57. Brazil Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Argentina Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Chile Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Middle East and Africa Manmade Version of Somatostatin Market Size by Country in 2025 Figure 61. Middle East and Africa Manmade Version of Somatostatin Sales Market Share by Country (2021-2032) Figure 62. Middle East and Africa Manmade Version of Somatostatin Revenue Market Share by Country (2021-2032) Figure 63. Egypt Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. South Africa Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Israel Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Türkiye Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. GCC Countries Manmade Version of Somatostatin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Global Manmade Version of Somatostatin Sales Market Share by Type (2021-2032) Figure 69. Global Manmade Version of Somatostatin Revenue Market Share by Type (2021-2032) Figure 70. Global Manmade Version of Somatostatin Price (US$/Unit) by Type (2021-2032) Figure 71. Global Manmade Version of Somatostatin Sales Market Share by Application (2021-2032) Figure 72. Global Manmade Version of Somatostatin Revenue Market Share by Application (2021-2032) Figure 73. Global Manmade Version of Somatostatin Price (US$/Unit) by Application (2021-2032) Figure 74. Manmade Version of Somatostatin Value Chain Figure 75. Manmade Version of Somatostatin Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Manmade Version of Somatostatin Industry Opportunities and Challenges

Scope & coverage.

Types
  • Pasireotide
  • Lanreotide
  • Octreotide
  • Other
Applications
  • Cushing Syndrome
  • Neuroendocrine Tumors
  • Acromegaly
  • Other
Companies covered
  • Advanz Pharma
  • Chiesi Farmaceutici S.p.A
  • Cipla
  • Fresenius Kabi
  • Gland Pharma
  • Heritage Pharmaceuticals
  • Ipsen
  • Mylan
  • Novartis
  • Recordati Rare Diseases
  • Sagent Pharmaceuticals
  • Sun Pharmaceutical
  • Teva
  • West-Ward Pharmaceuticals
  • Chengdu Tiantaishan pharmaceutical
  • Hainan Shuangcheng Pharmaceuticals
  • Hybio Pharmaceutical
  • Sihuan Pharmaceutical
  • Suzhou Tianma Pharmaceutical

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Manmade Version of Somatostatin Market Size (2021-2032)
  4. 2.2.2 Global Manmade Version of Somatostatin Sales (2021-2032)
  5. 2.2.3 Global Manmade Version of Somatostatin Market Average Price (2021-2032)
  6. 2.3 Manmade Version of Somatostatin by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Pasireotide
  9. 2.3.3 Lanreotide
  10. 2.3.4 Octreotide
  11. 2.3.5 Other
  12. 2.4 Manmade Version of Somatostatin by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Cushing Syndrome
  15. 2.4.3 Neuroendocrine Tumors
  16. 2.4.4 Acromegaly
  17. 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Manmade Version of Somatostatin Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Manmade Version of Somatostatin Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Manmade Version of Somatostatin Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Manmade Version of Somatostatin Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Manmade Version of Somatostatin Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Manmade Version of Somatostatin, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Manmade Version of Somatostatin, Product Type & Application
  8. 3.8 Global Manufacturers of Manmade Version of Somatostatin, Established Date
  9. 3.9 Global Manmade Version of Somatostatin Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Advanz Pharma
  2. 4.1.1 Advanz Pharma Company Information
  3. 4.1.2 Advanz Pharma Business Overview
  4. 4.1.3 Advanz Pharma Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Advanz Pharma Manmade Version of Somatostatin Product Portfolio
  6. 4.1.5 Advanz Pharma Recent Developments
  7. 4.2 Chiesi Farmaceutici S.p.A
  8. 4.2.1 Chiesi Farmaceutici S.p.A Company Information
  9. 4.2.2 Chiesi Farmaceutici S.p.A Business Overview
  10. 4.2.3 Chiesi Farmaceutici S.p.A Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Chiesi Farmaceutici S.p.A Manmade Version of Somatostatin Product Portfolio
  12. 4.2.5 Chiesi Farmaceutici S.p.A Recent Developments
  13. 4.3 Cipla
  14. 4.3.1 Cipla Company Information
  15. 4.3.2 Cipla Business Overview
  16. 4.3.3 Cipla Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Cipla Manmade Version of Somatostatin Product Portfolio
  18. 4.3.5 Cipla Recent Developments
  19. 4.4 Fresenius Kabi
  20. 4.4.1 Fresenius Kabi Company Information
  21. 4.4.2 Fresenius Kabi Business Overview
  22. 4.4.3 Fresenius Kabi Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Fresenius Kabi Manmade Version of Somatostatin Product Portfolio
  24. 4.4.5 Fresenius Kabi Recent Developments
  25. 4.5 Gland Pharma
  26. 4.5.1 Gland Pharma Company Information
  27. 4.5.2 Gland Pharma Business Overview
  28. 4.5.3 Gland Pharma Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Gland Pharma Manmade Version of Somatostatin Product Portfolio
  30. 4.5.5 Gland Pharma Recent Developments
  31. 4.6 Heritage Pharmaceuticals
  32. 4.6.1 Heritage Pharmaceuticals Company Information
  33. 4.6.2 Heritage Pharmaceuticals Business Overview
  34. 4.6.3 Heritage Pharmaceuticals Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Heritage Pharmaceuticals Manmade Version of Somatostatin Product Portfolio
  36. 4.6.5 Heritage Pharmaceuticals Recent Developments
  37. 4.7 Ipsen
  38. 4.7.1 Ipsen Company Information
  39. 4.7.2 Ipsen Business Overview
  40. 4.7.3 Ipsen Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Ipsen Manmade Version of Somatostatin Product Portfolio
  42. 4.7.5 Ipsen Recent Developments
  43. 4.8 Mylan
  44. 4.8.1 Mylan Company Information
  45. 4.8.2 Mylan Business Overview
  46. 4.8.3 Mylan Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Mylan Manmade Version of Somatostatin Product Portfolio
  48. 4.8.5 Mylan Recent Developments
  49. 4.9 Novartis
  50. 4.9.1 Novartis Company Information
  51. 4.9.2 Novartis Business Overview
  52. 4.9.3 Novartis Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Novartis Manmade Version of Somatostatin Product Portfolio
  54. 4.9.5 Novartis Recent Developments
  55. 4.10 Recordati Rare Diseases
  56. 4.10.1 Recordati Rare Diseases Company Information
  57. 4.10.2 Recordati Rare Diseases Business Overview
  58. 4.10.3 Recordati Rare Diseases Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Recordati Rare Diseases Manmade Version of Somatostatin Product Portfolio
  60. 4.10.5 Recordati Rare Diseases Recent Developments
  61. 4.11 Sagent Pharmaceuticals
  62. 4.11.1 Sagent Pharmaceuticals Company Information
  63. 4.11.2 Sagent Pharmaceuticals Business Overview
  64. 4.11.3 Sagent Pharmaceuticals Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Sagent Pharmaceuticals Manmade Version of Somatostatin Product Portfolio
  66. 4.11.5 Sagent Pharmaceuticals Recent Developments
  67. 4.12 Sun Pharmaceutical
  68. 4.12.1 Sun Pharmaceutical Company Information
  69. 4.12.2 Sun Pharmaceutical Business Overview
  70. 4.12.3 Sun Pharmaceutical Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Sun Pharmaceutical Manmade Version of Somatostatin Product Portfolio
  72. 4.12.5 Sun Pharmaceutical Recent Developments
  73. 4.13 Teva
  74. 4.13.1 Teva Company Information
  75. 4.13.2 Teva Business Overview
  76. 4.13.3 Teva Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Teva Manmade Version of Somatostatin Product Portfolio
  78. 4.13.5 Teva Recent Developments
  79. 4.14 West-Ward Pharmaceuticals
  80. 4.14.1 West-Ward Pharmaceuticals Company Information
  81. 4.14.2 West-Ward Pharmaceuticals Business Overview
  82. 4.14.3 West-Ward Pharmaceuticals Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 West-Ward Pharmaceuticals Manmade Version of Somatostatin Product Portfolio
  84. 4.14.5 West-Ward Pharmaceuticals Recent Developments
  85. 4.15 Chengdu Tiantaishan pharmaceutical
  86. 4.15.1 Chengdu Tiantaishan pharmaceutical Company Information
  87. 4.15.2 Chengdu Tiantaishan pharmaceutical Business Overview
  88. 4.15.3 Chengdu Tiantaishan pharmaceutical Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Chengdu Tiantaishan pharmaceutical Manmade Version of Somatostatin Product Portfolio
  90. 4.15.5 Chengdu Tiantaishan pharmaceutical Recent Developments
  91. 4.16 Hainan Shuangcheng Pharmaceuticals
  92. 4.16.1 Hainan Shuangcheng Pharmaceuticals Company Information
  93. 4.16.2 Hainan Shuangcheng Pharmaceuticals Business Overview
  94. 4.16.3 Hainan Shuangcheng Pharmaceuticals Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Hainan Shuangcheng Pharmaceuticals Manmade Version of Somatostatin Product Portfolio
  96. 4.16.5 Hainan Shuangcheng Pharmaceuticals Recent Developments
  97. 4.17 Hybio Pharmaceutical
  98. 4.17.1 Hybio Pharmaceutical Company Information
  99. 4.17.2 Hybio Pharmaceutical Business Overview
  100. 4.17.3 Hybio Pharmaceutical Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Hybio Pharmaceutical Manmade Version of Somatostatin Product Portfolio
  102. 4.17.5 Hybio Pharmaceutical Recent Developments
  103. 4.18 Sihuan Pharmaceutical
  104. 4.18.1 Sihuan Pharmaceutical Company Information
  105. 4.18.2 Sihuan Pharmaceutical Business Overview
  106. 4.18.3 Sihuan Pharmaceutical Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Sihuan Pharmaceutical Manmade Version of Somatostatin Product Portfolio
  108. 4.18.5 Sihuan Pharmaceutical Recent Developments
  109. 4.19 Suzhou Tianma Pharmaceutical
  110. 4.19.1 Suzhou Tianma Pharmaceutical Company Information
  111. 4.19.2 Suzhou Tianma Pharmaceutical Business Overview
  112. 4.19.3 Suzhou Tianma Pharmaceutical Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Suzhou Tianma Pharmaceutical Manmade Version of Somatostatin Product Portfolio
  114. 4.19.5 Suzhou Tianma Pharmaceutical Recent Developments
5 Global Manmade Version of Somatostatin Market Scenario by Region
  1. 5.1 Global Manmade Version of Somatostatin Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Manmade Version of Somatostatin Sales by Region: 2021-2032
  3. 5.2.1 Global Manmade Version of Somatostatin Sales by Region: 2021-2026
  4. 5.2.2 Global Manmade Version of Somatostatin Sales by Region: 2027-2032
  5. 5.3 Global Manmade Version of Somatostatin Revenue by Region: 2021-2032
  6. 5.3.1 Global Manmade Version of Somatostatin Revenue by Region: 2021-2026
  7. 5.3.2 Global Manmade Version of Somatostatin Revenue by Region: 2027-2032
  8. 5.4 North America Manmade Version of Somatostatin Market Facts & Figures by Country
  9. 5.4.1 North America Manmade Version of Somatostatin Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Manmade Version of Somatostatin Sales by Country (2021-2032)
  11. 5.4.3 North America Manmade Version of Somatostatin Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Manmade Version of Somatostatin Market Facts & Figures by Country
  16. 5.5.1 Europe Manmade Version of Somatostatin Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Manmade Version of Somatostatin Sales by Country (2021-2032)
  18. 5.5.3 Europe Manmade Version of Somatostatin Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Manmade Version of Somatostatin Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Manmade Version of Somatostatin Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Manmade Version of Somatostatin Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Manmade Version of Somatostatin Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Manmade Version of Somatostatin Market Facts & Figures by Country
  41. 5.7.1 South America Manmade Version of Somatostatin Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Manmade Version of Somatostatin Sales by Country (2021-2032)
  43. 5.7.3 South America Manmade Version of Somatostatin Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Manmade Version of Somatostatin Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Manmade Version of Somatostatin Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Manmade Version of Somatostatin Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Manmade Version of Somatostatin Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Manmade Version of Somatostatin Sales by Type (2021-2032)
  2. 6.1.1 Global Manmade Version of Somatostatin Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Manmade Version of Somatostatin Sales Market Share by Type (2021-2032)
  4. 6.2 Global Manmade Version of Somatostatin Revenue by Type (2021-2032)
  5. 6.2.1 Global Manmade Version of Somatostatin Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Manmade Version of Somatostatin Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Manmade Version of Somatostatin Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Manmade Version of Somatostatin Sales by Application (2021-2032)
  2. 7.1.1 Global Manmade Version of Somatostatin Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Manmade Version of Somatostatin Sales Market Share by Application (2021-2032)
  4. 7.2 Global Manmade Version of Somatostatin Revenue by Application (2021-2032)
  5. 7.2.1 Global Manmade Version of Somatostatin Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Manmade Version of Somatostatin Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Manmade Version of Somatostatin Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Manmade Version of Somatostatin Value Chain Analysis
  2. 8.1.1 Manmade Version of Somatostatin Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Manmade Version of Somatostatin Production Mode & Process
  5. 8.2 Manmade Version of Somatostatin Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Manmade Version of Somatostatin Distributors
  8. 8.2.3 Manmade Version of Somatostatin Customers
9 Global Manmade Version of Somatostatin Analyzing Market Dynamics
  1. 9.1 Manmade Version of Somatostatin Industry Trends
  2. 9.2 Manmade Version of Somatostatin Industry Drivers
  3. 9.3 Manmade Version of Somatostatin Industry Opportunities and Challenges
  4. 9.4 Manmade Version of Somatostatin Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst